Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction

Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis

(2015) Bing H. Wang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Neprilysin inhibitors preserve renal function in heart failure

(2015) Fiona Bodey et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

(2012) Sarah Mangiafico et al.   EUROPEAN HEART JOURNAL

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

(2009) Jessie Gu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Biology of the Natriuretic Peptides

(2008) Abelardo Martinez-Rumayor et al.   AMERICAN JOURNAL OF CARDIOLOGY